SeaStar Medical Holding Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. September 6, 2024 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - SeaStar Medical Holding Corporation is facing a class action lawsuit due to alleged violations of federal securities laws, with investors encouraged to file claims for losses incurred during the specified class period [1][3]. Group 1: Legal Action and Investor Information - The Portnoy Law Firm is representing investors who purchased SeaStar securities between October 31, 2022, and March 26, 2024, with a deadline of September 6, 2024, to file a lead plaintiff motion [1]. - Investors can contact the law firm for a complimentary case evaluation and to discuss options for recovering losses [2]. Group 2: Allegations Against SeaStar - The complaint alleges that SeaStar and its executives made false or misleading statements regarding compliance controls for the HDE Application, leading to exaggerated regulatory prospects [3]. - Specific issues cited include inadequate financial controls, potential restatements of past financial statements, and misleading public statements about the company's business and financial prospects [3]. Group 3: Financial Restatement Announcement - On March 27, 2024, SeaStar announced it would restate financial statements for the fiscal year ending December 31, 2022, and interim periods through September 30, 2023, affecting the accounting of certain outstanding warrants and a prepaid forward purchase arrangement [4]. - The CEO indicated that the restatement would not significantly impact operations or cash position, but was related to non-cash accounting items [4]. Group 4: Market Reaction - Following the announcement of the restatement, SeaStar's stock price fell by $0.04 per share, or 5.41%, closing at $0.70 per share on March 27, 2024 [5].